Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. On this week’s episode of “The Readout LOUD”: The FDA is once again searching for a new leader, a closely tracked lung cancer drug suffers an FDA rejection, and China’s largest drugmakers ranked. We invite you to listen to this pre-Thanksgiving episode of your favorite biotech podcast, where our attention turns to D.C. The Trump administration withdrew the nomination of Heidi Overton to become the next FDA commissioner hours before a pivotal Senate committee vote. STAT’s D.C. correspondent Margaret Manto joins us to explain why Overton was tossed and who might be next in line to run the FDA. We’ll also chatter away about this week’s news, including the FDA’s rejection of a lung cancer drug from the U.S.-based biotech Summit Therapeutics and the Chinese drug maker Akeso. And speaking of China, STAT just launched a new index ranking China’s largest drugmakers. We’ll discuss how the list was made and why tracking Chinese biotech has become so important. Make sure to subscribe to “The Readout LOUD” on Apple Podcasts, Spotify, or wherever you get your podcasts.
FDA’s search for a new leader, and China’s largest drugmakers
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.